Skip to main content

Table 5 Multiple linear regression with TLR7 and TLR9 expressions as independent variables in lupus patients

From: Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus

Risk factors

Adjusted coefficient (95%)

P-value

Adjusted R2

TLR7 level

  

0.592

HPV infection

-0.815 (-6.827 to -1.751)

0.002

 

Cumulative dose of prednisolone in the past 15 years, gm

-0.356 (-0.014 to -0.001)

0.026

 

High-risk HPV infection

0.217 (-1.487 to 3.926)

0.359

 

Hydroxychloroquine therapy ever

0.012 (-1.919 to 2.046)

0.067

 

TLR9 level

  

0.391

HPV infection

-0.313 (-10.395 to -1.170)

0.015

 

SLEDAI

0.474 (0.841 to 2.576)

< 0.001

 

Cumulative dose of hydroxychloroquine in the past 15 years, gm

-0.268 (-0.012 to 0.000)

0.041

 

Duration receiving treatment of Azathioprine, month

-0.047 (-0.059 to 0.040)

0.706

 
  1. HPV, human papillomavirus; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; TLR, toll-like receptor